Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure

作者：Ungar Bella; Haj Natour Ola; Kopylov Uri; Yavzori Miri; Fudim Ella; Picard Orit; Loebstein Ronen; Lahat Adi; Maor Yaakov; Avidan Benjamin; Lang Alon; Weiss Batia; Chowers Yehuda; Eliakim Rami; Ben Horin Shomron^*

来源：Medicine, 2015, 94(18): e673.

DOI：10.1097/MD.0000000000000673

Infliximab is an anti-tumor necrosis factor (TNF) used for treatment of inflammatory bowel disease (IBD) as well as rheumatoid arthritis, psoriasis, and other inflammatory conditions. Antibodies to infliximab (ATI) develop in 45% of infliximab-treated IBD patients and are correlated with loss of clinical response. Scarce data exist as to factors which predict infliximab immunogenicity.
To investigate factors that may predict formation of antibodies to infliximab (ATI) and infliximab therapy failure.
An observational study of consecutive IBD patients treated with infliximab between 2009 and 2013 was performed. Trough levels of ATI were measured. Patients were monitored for disease activity using clinical activity indexes and were classified according to ATI formation and clinical response. All clinical and demographic parameters were analyzed for association with the designated outcomes.
One hundred fifty-nine patients were included and 1505 sera were tested. On multivariate analysis, Jewish Ashkenazi ethnicity was protective against both development of ATI (odds ratio [OR] 0.35, 95% confidence interval [CI] 0.17-0.7, P = 0.005) and treatment failure (OR 0.29, 95% CI 0.13-0.66, P = 0.003). Concomitant immunomodulator therapy was also negatively associated with immunogenicity and infliximab therapy failure (OR 0.31, 95% CI 0.15-0.65, P = 0.002; OR 0.42, 95% CI 0.180.99, P Jewish Ashkenazi ethnicity is protective of ATI formation and infliximab therapy failure. These findings suggest a role for ethnicity, and implicitly for genetic predisposition, in modulating the risk of anti-TNF immunogenicity and treatment unresponsiveness.

• 出版日期2015-5